Anika Therapeutics - ANIK Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ANIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares.
View ANIK analyst ratings or view top-rated stocks.

2 analysts have issued 1-year target prices for Anika Therapeutics' stock. Their ANIK share price forecasts range from $26.00 to $31.00. On average, they anticipate the company's share price to reach $28.50 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price.
View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts.

Anika Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, ANIK stock has decreased by 5.2% and is now trading at $28.05.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ANIK earnings forecast.

Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its earnings results on Thursday, November, 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.26. The biotechnology company earned $39.54 million during the quarter, compared to analysts' expectations of $36.45 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 2.43% and a negative net margin of 9.51%. During the same period in the prior year, the business earned ($0.45) earnings per share.

ETFs with the largest weight of Anika Therapeutics (NASDAQ:ANIK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Royce Quant Small-Cap Quality Value ETF (SQLV), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Vanguard U.S. Minimum Volatility ETF (VFMV) and Dimensional US Marketwide Value ETF (DFUV).Dimensional US Small Cap Value ETF (DFSV).

Anika Therapeutics issued an update on its FY 2023 earnings guidance on Monday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $158.00 million-$163.00 million, compared to the consensus revenue estimate of $168.40 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Anika Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (6.57%), Renaissance Technologies LLC (4.08%), Caligan Partners LP (4.05%), Boothbay Fund Management LLC (2.52%), Geode Capital Management LLC (1.89%) and Portolan Capital Management LLC (1.42%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, James Loerop, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends.

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANIK stock can currently be purchased for approximately $28.05.

Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $410.37 million and generates $156.24 million in revenue each year. The biotechnology company earns $-14,860,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis.

The company employs 297 workers across the globe.

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.